Last reviewed · How we verify
GT201
At a glance
| Generic name | GT201 |
|---|---|
| Sponsor | Grit Biotechnology |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors (NA)
- Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (EARLY_PHASE1)
- Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors (PHASE1, PHASE2)
- Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients with Advanced Lung Cancer (NA)
- Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/recurrent Advanced Solid Tumors (PHASE1)
- Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (advanced Cervical Cancer) (NA)
- GT201 Injection in Combination with Teraplizumab Injection for Treatment of Patients with Non-small Cell Lung Cancer (NA)
- GT201 Injection For The Treatment Of Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GT201 CI brief — competitive landscape report
- GT201 updates RSS · CI watch RSS
- Grit Biotechnology portfolio CI